GlassScriptPhysician profile
Sam S Bang
NPI 1447224118
$3,855.69
in general payments reported to CMS, 2019-2025
18 companies · $976 in 2025
The $976 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $252 · 2021: $607 · 2022: $421 · 2023: $601 · 2024: $797 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,374.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $912.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $686.41 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $582.02 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $427.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $324.65 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Pfizer INC. | $195.15 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $163.73 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $127.37 | 2024-2025 | Voquezna |
| Abbvie INC. | $115.48 | 2021-2025 | Qulipta |
| E.R. Squibb & Sons, L.L.C. | $85.37 | 2021-2023 | Camzyos |
| Glaxosmithkline, LLC. | $47.33 | 2019-2022 | |
| Sanofi Pasteur INC. | $43.19 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $41.82 | 2022 | |
| Amarin Pharma, INC. | $29.65 | 2021 | |
| Exact Sciences Corporation | $25.30 | 2025 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.08 | 2022 | |
| Amgen INC. | $17.60 | 2025 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Bang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.